Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 12;13(4):354.
doi: 10.3390/antibiotics13040354.

Pharmacokinetics and Nephrotoxicity of Polymyxin MRX-8 in Rats: A Novel Agent against Resistant Gram-Negative Bacteria

Xingyi Qu  1   2   3 , Chenxue Guo  1   2   3 , Shaojun Liu  4 , Xin Li  1   2   3 , Lin Xi  1   2   3 , Xiaofen Liu  1   2   3 , Jing Zhang  1   2   3   5
Affiliations

Pharmacokinetics and Nephrotoxicity of Polymyxin MRX-8 in Rats: A Novel Agent against Resistant Gram-Negative Bacteria

Xingyi Qu et al. Antibiotics (Basel). .

Abstract

MRX-8 is a novel polymyxin for carbapenem-resistant Gram-negative infections that has been recently evaluated in Phase I clinical trials. Herein, its pharmacokinetics (PK) and nephrotoxicity in rats are reported for the first time. This study aimed at pre-clinical PK and safety assessments. An LC-MS/MS method was developed to determine concentrations of MRX-8 and its major deacylation metabolite, MRX-8039, in rat plasma. Animals were administered a single dose of MRX-8 (2, 4, 6, and 8 mg/kg) or comparator polymyxin B (PMB) (4 and 8 mg/kg) to compare the kidney injury known for the polymyxin drug class. Nephrotoxicity was evaluated using serum creatinine, blood urea nitrogen (BUN) biomarkers, and renal histopathology. In rats, MRX-8 displayed linear PK within the range of 2-8 mg/kg, with approximately 4% of MRX-8 converted to MRX-8039. MRX-8 induced only mild increases in serum creatinine and BUN levels, with an apparent decrease in nephrotoxicity within 24 h, in contrast to PMB, which exhibited a significant and more persistent toxicity. Additional nephrotoxicity biomarkers (plasma NGAL and urinary NGAL, KIM-1, and TIMP-1) have confirmed attenuated MRX-8 kidney injury. Histopathology has revealed significantly greater cellular/tissue toxicity for PMB as compared to MRX-8 (variances of p = 0.008 and p = 0.048 vs. saline control, respectively). Thus, MRX-8 induces a mild and reversible kidney injury in rats compared to PMB. These data support a continued evaluation of the novel polymyxin in human trials.

Keywords: MRX-8; MRX-8039; nephrotoxicity; pharmacokinetics; polymyxins.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Structures of MRX-8, metabolite MRX-8039, and polymyxin B. (a) Chemical structures and transformation of MRX-8 and MRX-8039; (b) Chemical structure of polymyxin B.
Figure 2
Figure 2
Typical chromatograms of MRX-8, MRX-8039, and IS spiked in rat plasma. (a) Chromatogram of MRX-8 under parent ion monitoring mode; (b) chromatogram of MRX-8039 under parent ion monitoring mode; (c) chromatogram of MRX-8 in blank plasma without spiking MRX-8 and MRX-8039; (d) chromatogram of MRX-8039 in blank plasma without spiking MRX-8 and MRX-8039; (e) chromatogram of MRX-8 in plasma at LLOQ level; (f) chromatogram of MRX-8039 in plasma at LLOQ level; (g) chromatogram of MRX-8 in plasma sample after subcutaneous administration of MRX-8; (h) chromatogram of MRX-8039 in plasma sample after subcutaneous administration of MRX-8; (i) chromatogram of IS spiked in plasma (20 mg/L).
Figure 3
Figure 3
The concentration–time curves of MRX-8, MRX-8039, and PMB in rat plasma after subcutaneous administration. (a) Concentration–time curves of MRX-8. (b) Semi-logarithmic concentration–time curves of MRX-8. (c) Concentration–time curves of MRX-8039. (d) Semi-logarithmic concentration–time curves of MRX-8039. (e) Concentration–time curves of PMB. (f) Semi-logarithmic concentration–time curves of PMB. The green, yellow, blue, and pink lines indicate subcutaneous administration of 2 mg/kg, 4 mg/kg, 6 mg/kg, and 8 mg/kg MRX-8, respectively. The light and dark blue lines indicated subcutaneous administered PMB 4 mg/kg and 8 mg/kg, respectively. The error bars indicate the corresponding standard deviation (n = 5). PMB: polymyxin B.
Figure 4
Figure 4
The creatinine and BUN levels after subcutaneous administration of saline, MRX-8, and PMB at 8 h and 24 h. (a) Creatinine levels at 8 h. (b) Creatinine levels at 24 h. (c) BUN levels at 8 h. (d) BUN levels at 24 h. Control: saline group; PMB: polymyxin B; BUN: blood urea nitrogen; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Figure 5
Figure 5
The NGAL levels in plasma and NGAL, KIM-1, and TIMP-1 levels in urine at 24 h after subcutaneous administration of saline, MRX-8, and PMB of 4 mg/kg and 8 mg/kg. (a) NGAL levels in plasma; (b) NGAL levels in urine; (c) KIM-1 levels in urine; (d) TIMP-1 levels in urine. NGAL: neutrophil gelatinase-associated lipocalin; KIM-1: kidney injury molecule-1; TIMP-1: tissue inhibitor of metalloproteinase-1; control: saline group, PMB: polymyxin B; * p < 0.05, ** p < 0.01.
Figure 6
Figure 6
PAS staining of kidney tissue after 24 h of administration with saline, MRX-8, and PMB. (a) Experimental design. (b) Kidney tissue after saline administration. (c) Kidney tissue for MRX-8 at 4 mg/kg. (d) Kidney tissue for PMB at 4 mg/kg. (e) Kidney tissue for MRX-8 at 8 mg/kg. (f) Kidney tissue for PMB at 8 mg/kg. Blue arrows: brush border loss; black arrows: basal membrane exposure; red arrows: nuclear shrinkage; green arrows: tubular formation.
See this image and copyright information in PMC

References

    1. Nang S.C., Azad M.A.K., Velkov T., Zhou Q.T., Li J. Rescuing the Last-Line Polymyxins: Achievements and Challenges. Pharmacol. Rev. 2021;73:679–728. doi: 10.1124/pharmrev.120.000020. - DOI - PMC - PubMed
    1. Jean S.S., Gould I.M., Lee W.S., Hsueh P.R. New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship. Drugs. 2019;79:705–714. doi: 10.1007/s40265-019-01112-1. - DOI - PubMed
    1. Vardakas K.Z., Falagas M.E. Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: A systematic review and meta-analysis. Int. J. Antimicrob. Agents. 2017;49:233–238. doi: 10.1016/j.ijantimicag.2016.07.023. - DOI - PubMed
    1. Bian X., Qu X., Zhang J., Nang S.C., Bergen P.J., Zhou Q.T., Chan H.K., Feng M., Li J. Pharmacokinetics and pharmacodynamics of peptide antibiotics. Adv. Drug Deliv. Rev. 2022;183:114171. doi: 10.1016/j.addr.2022.114171. - DOI - PMC - PubMed
    1. Wagenlehner F., Lucenteforte E., Pea F., Soriano A., Tavoschi L., Steele V.R., Henriksen A.S., Longshaw C., Manissero D., Pecini R., et al. Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins. Clin. Microbiol. Infect. 2021;27:671–686. doi: 10.1016/j.cmi.2020.12.009. - DOI - PubMed